长春瑞滨联合卡培他滨治疗转移性乳腺癌的临床研究

A clinical study on combination of vinorelbine and capecitabine to patients with advanced breast cancer

目的观察长春瑞滨联合卡培他滨对紫杉类和/或蒽环类药物治疗后失败的转移性乳腺癌的疗效、安全性。方法39例晚期乳腺癌患者均给予长春瑞滨25mg·m-2,第一,八天;希罗达口服,950mg·m-2,1日2次,餐后服用,连续服用14d。21d为1周期,至少完成2周期化疗。每周期评价毒性反应,2周期化疗后评价疗效。结果39例患者有效率达46.2%。无CR病人,PR18例(46.2%),SD13例(33.3%),PD8例(20.5%)。中位肿瘤进展时间(TTP)为6.4个月(1～18个月)。最常见的不良反应为手足综合征、骨髓抑制、神经毒性、胃肠道反应等,多为轻度到中度。结论长春瑞滨联合卡培他滨对紫杉类和/或蒽环类药物治疗后失败的转移性乳腺癌有较好的疗效,毒性可以耐受。

OBJECTIVE To analyze the efficacy and safety of combination of vinorelbine and capecitabine in the treatment for metastatic breast cancer （MBC） patients in whom paclitaxel and/or anthracicline treatment have failed. METHODS Thirty-nine patients with MBC received the combination consisting of vinorelbine 25mg/m^2 on days 1, 8 plus capeeitabine 950mg/m^2 bid given from day 1 to day 14. All patients received chemotherapy every 3 weeks for at least two cycles. Side effects were investigated in each cycle, efficacy was evaluated after two cycles.RESULTS Among these 39 patients, the objective response rate（CR ＋ PR） was 46.2% .The partial response was achieved in 18 patients （46.2%）, stable disease in 13 patients （33.3%）, and progressive disease was observed in 8 patients （20.5 % ）, but no patient achieved complete response. The median time to disease progression（TTP） was 6.4 months（range, 1-18 months）. The most frequent clinical adverse events were hand-foot syndrome, neutropenia, neural toxicity, nausea, vomitimg.The majority of events were mild to moderate.CONCLUSION The combination of the vinorelbine and capecitabine is very well tolerated and effective to patients who were resistant to paclitaxel and/or anthracycline.